Seroprevalence of Hepatitis C Virus and Factors Associated with It in Armenia, 2021.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
11 Sep 2024
Historique:
received: 24 07 2024
accepted: 27 08 2024
medline: 29 9 2024
pubmed: 28 9 2024
entrez: 28 9 2024
Statut: epublish

Résumé

Hepatitis C virus (HCV) infection is among the leading causes of cirrhosis and hepatocellular carcinoma. Knowledge of its prevalence and risk factors can help to effectively fight the virus. This study was the first to investigate the seroprevalence of HCV, its genotypes, and factors associated with it among the general adult population of Armenia selected countrywide via cluster sampling. Anti-HCV antibodies were detected using third-generation immunoassay. Polymerase chain reaction and genotyping was performed among anti-HCV-positive individuals. Shortly after testing, the participants underwent a telephone survey. Logistic regression models were fitted to identify factors associated with anti-HCV antibody positivity and chronic HCV infection. The prevalence of anti-HCV antibodies among 3831 tested individuals was 2% (99% CI 1.4, 2.5), and chronic HCV infection was 0.7% (99% CI 0.4, 1.0), with genotypes 3 and 2 being the most common. The risk factors for chronic HCV infection included self-reported chronic liver disease (95% CI 1.47, 15.28), having tattoos (95% CI 1.34, 10.94), ever smoking (95% CI 1.16, 9.18), and testing positive for hepatitis B virus core antibody (95% CI 1.02, 7.17). These risk factors demonstrate that there could be room for strengthening infection control measures to prevent the transmission of HCV in Armenia.

Identifiants

pubmed: 39339922
pii: v16091446
doi: 10.3390/v16091446
pii:
doi:

Substances chimiques

Hepatitis C Antibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : WHO Regional Office for Europe
ID : (no grant number)

Auteurs

Anahit Demirchyan (A)

Turpanjian College of Health Sciences, American University of Armenia, 40 Marshal Baghramyan Ave., Yerevan 0019, Armenia.

Antons Mozalevskis (A)

Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, 1211 Geneva, Switzerland.

Serine Sahakyan (S)

Turpanjian College of Health Sciences, American University of Armenia, 40 Marshal Baghramyan Ave., Yerevan 0019, Armenia.

Lusine Musheghyan (L)

Turpanjian College of Health Sciences, American University of Armenia, 40 Marshal Baghramyan Ave., Yerevan 0019, Armenia.

Lusine Aslanyan (L)

Turpanjian College of Health Sciences, American University of Armenia, 40 Marshal Baghramyan Ave., Yerevan 0019, Armenia.

Diana Muradyan (D)

Turpanjian College of Health Sciences, American University of Armenia, 40 Marshal Baghramyan Ave., Yerevan 0019, Armenia.

Narina Sargsyants (N)

National Institute of Health, Ministry of Health, Republic of Armenia, Yerevan 0051, Armenia.

Gayane Ghukasyan (G)

World Health Organization Country Office in Armenia, Yerevan 0015, Armenia.

Varduhi Petrosyan (V)

Turpanjian College of Health Sciences, American University of Armenia, 40 Marshal Baghramyan Ave., Yerevan 0019, Armenia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH